DECRYPTION – Molnupiravir, the most advanced antiviral in the fight against the virus responsible for Covid-19, raises hope after very encouraging intermediate successes.
After the spectacular success of the first Covid vaccines, are we close to seeing comparable progress on the treatment front? In any case, this is the hope aroused by an experimental drug, a simple oral tablet, whose clinical trials are continuing after very encouraging intermediate successes.
A first phase 2 clinical trial presented at the International Conference on Retroviruses and Opportunistic Infections (CROI), shows that the Sars-CoV-2 infection was eliminated in five days in 47 patients with the new antiviral, at code name EIDD-2801, now called molnupiravir. In patients treated with a placebo, on the other hand, a quarter of them still carried the infectious virus. “This is a very interesting candidate for curing patients at an early stage of the disease”, underlines Bruno Canard, coronavirus specialist at the University of Aix-Marseille.
Molnupiravir is the most advanced antiviral in the fight against
This article is for subscribers only. You have 81% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
Already subscribed? Log in